{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["51"],"submitter":["Ascaso-Del-Rio A"],"pubmed_abstract":["<h4>Background</h4>There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens.<h4>Methods</h4>This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses. Anti-RBD antibodies level and neutralising titres (NT50) against G614, Beta, Mu, Delta and Omicron variants were analy"],"journal":["EClinicalMedicine"],"pagination":["101542"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9249303"],"repository":["biostudies-literature"],"pubmed_title":["Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study."],"pmcid":["PMC9249303"],"pubmed_authors":["Perez-Olmeda M","Imaz-Ayo N","Perez-Ingidua C","Vargas-Castrillon E","Arrizabalaga J","Arana-Arri E","Alcami J","RescueVac study Group","Diez-Fuertes F","Garcia-Perez J","Castillo de la Osa M","Portoles A","de la Torre-Tarazona HE","Mariano Lazaro A","Riano Fernandez I","Astasio Gonzalez O","Hernandez Gutierrez L","Meijide S","Bermejo M","Vergara I","Ascaso-Del-Rio A"],"additional_accession":[]},"is_claimable":false,"name":"Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.","description":"<h4>Background</h4>There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens.<h4>Methods</h4>This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses. Anti-RBD antibodies level and neutralising titres (NT50) against G614, Beta, Mu, Delta and Omicron variants were analy","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-26T21:07:35.157Z","creation":"2022-07-23T08:39:36.107Z"},"accession":"S-EPMC9249303","cross_references":{"pubmed":["35795398"],"doi":["10.1016/j.eclinm.2022.101542"]}}